FX06

DRUG3 trials

Sponsors

F4-Pharma Ges.m.b.H., Fibrex Medical Research & Development GmbH, Assistance Publique - Hôpitaux de Paris

Conditions

Acute Respiratory Distress Syndrome (ARDS)ArdsCoronary DiseaseCovid19Myocardial InfarctionMyocardial IschemiaPneumonia

Phase 2

Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury

CompletedNCT00326976

Fibrex Medical Research & Development GmbHCoronary Disease, Myocardial Infarction, Myocardial Ischemia

Start: 2006-08-31End: 2007-11-30Updated: 2007-12-04

FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia

CompletedNCT04618042

Assistance Publique - Hôpitaux de ParisArds, Covid19, Pneumonia

Start: 2020-11-13End: 2021-06-13Updated: 2021-06-22

Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0)

CompletedCTIS2024-519104-27-00

F4-Pharma Ges.m.b.H.Acute Respiratory Distress Syndrome (ARDS)

Start: 2022-03-08End: 2025-03-31Target: 263Updated: 2024-12-09

Related Papers

FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial

Critical Care2023-08-294 citations

Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial.

2009-02-01117 citations